Avastin-Injections in Age Related Macular Degeneration:<br>Prospective Study for Optimal Frequency and Follow-up Determination.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 360
研究概览
简要总结
ushchyk T, Amarakoon S, Martinez-CirianoJP, van den Born LI, Baarsma GS, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmol. 2013; 91(6): e456-461. PMID: 23773796 Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma S, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks. Acta Ophthalmol. 2019; 97(1): 107-112. PMID: 30369062 Visser MS, Amarakoon S, Missotten T, Timman R, Busschbach JJV. Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial. Qual Life Res. 2020 [Epub]. PMID: 32666333
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Informed consent;
- •2. Endophthalmitis risks have been made clear;
排除标准
- 未提供